Twist Bioscience
TWST · NASDAQ · Healthcare
$158.50
$7.01 (-4.42%) today
Market Cap
$2.60B
24h Volume
$338.1M
P/E Ratio
-21.3
52w High
$166.99
52w Low
$25.45
Est. AI Revenue
15%
7-Day Sparkline (Static)
Company facts
Performance
About Twist Bioscience
Twist Bioscience is a synthetic biology company. It manufactures synthetic DNA and sells it to biotech, pharma, and antibody discovery customers, earning revenue from DNA products used in drug discovery, diagnostics, and research.
Machine learning guides much of that work. Twist offers AI-guided DNA synthesis, machine learning tools for antibody design, and AI tools for biopharma customers. These help clients design better DNA libraries and antibodies before anything is made in the lab. The company also explores DNA as a medium for data storage.
Founded in 2013 and headquartered in South San Francisco, California, Twist trades on the NASDAQ, employs roughly 1,000 people, and is led by CEO Emily Leproust.
Twist Bioscience in the AI buildout
Twist Bioscience sits in the AI Healthcare layer as a tools supplier whose products feed AI-driven science. Demand for its synthetic DNA is partly pulled by AI-based drug discovery programs that need DNA libraries, and its own ML models guide antibody and library design. DNA data storage is a long shot option on the data economy. The core remains a synthesis tools business, so Supercycle scores its AI exposure at 15 out of 100.
TWST is tracked in AI Healthcare, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
TWST trades at $158.50, 94% of the way up its 52-week range of $25.45 to $166.99.
Market cap
Market capitalization is $2.60B, with an AI Exposure Score of 15 out of 100.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Twist Bioscience do?
Twist manufactures synthetic DNA for biotech, pharma, and antibody discovery customers. Its products support drug discovery, diagnostics, and research, and it uses machine learning to guide DNA library and antibody design.
How is Twist Bioscience exposed to AI?
Modestly. Supercycle scores it 15 out of 100. AI-driven drug discovery creates demand for its DNA, and ML guides its designs, but the core business is selling synthesis tools, not AI itself.
What are Twist Bioscience's main products?
AI-guided DNA synthesis, machine learning antibody design, and AI tools for biopharma customers. It also explores DNA data storage, a speculative application that would tie synthetic DNA to the data economy.
Where is Twist Bioscience headquartered and who leads it?
Twist Bioscience is headquartered in South San Francisco, California, and led by CEO Emily Leproust. Founded in 2013, the company trades on the NASDAQ and employs roughly 1,000 people.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.